Quarterly report pursuant to Section 13 or 15(d)

Stock Based Compensation

v3.24.1.1.u2
Stock Based Compensation
3 Months Ended
Mar. 31, 2024
Share-Based Payment Arrangement [Abstract]  
Stock-Based Compensation
10.
Stock-Based Compensation

In connection with the Closing, the Company adopted the 2021 Equity Incentive Plan (the “2021 Plan”) and the 2021 Employee Stock Purchase Plan (“2021 ESPP”). The number of shares available for issuance under the 2021 Plan is increased on the first day of each fiscal year, beginning on January 1, 2022, in an amount as provided in the 2021 Plan. Pursuant to this automatic increase feature of the 2021 Plan, 1,054,867 shares were added as available for issuance thereunder on January 1, 2024. As of March 31, 2024, 818,433 shares were available for issuance under the 2021 Plan.

The number of shares available for issuance under the 2021 ESPP is increased on the first day of each fiscal year, beginning on January 1, 2022, in an amount as provided in the 2021 ESPP. Pursuant to this automatic increase feature of the 2021 ESPP, 210,973 shares were added as available for issuance thereunder on January 1, 2024. As of March 31, 2024, 743,659 shares were available for issuance under the 2021 ESPP.

The following table summarizes stock option activity under our equity compensation plans:

 

 

Number of
Options

 

 

Weighted-
Average
Exercise
Price

 

 

Weighted-
Average
Remaining
Contractual
Term

 

 

 

 

 

 

 

 

(in years)

 

Options outstanding as of December 31, 2023

 

 

2,198,552

 

 

$

17.11

 

 

 

5.0

 

Granted

 

 

 

 

$

 

 

 

 

Exercised

 

 

(37,536

)

 

$

7.13

 

 

 

 

Forfeited, canceled, or expired

 

 

(166,413

)

 

$

22.26

 

 

 

 

Options outstanding as of March 31, 2024

 

 

1,994,603

 

 

$

16.87

 

 

 

5.1

 

Vested and expected to vest at March 31, 2024

 

 

1,994,603

 

 

$

16.87

 

 

 

5.1

 

Exercisable at March 31, 2024

 

 

1,762,321

 

 

$

16.74

 

 

 

4.8

 

 

The Company received $267 in cash proceeds from options exercised during the three months ended March 31, 2024, and there were no options exercised during the three months ended March 31, 2023. There were no options granted during the three months ended March 31, 2024 and 2023.

The following table summarizes restricted stock unit ("RSU") activity under the 2021 Plan:

 

 

 

 

 

Number of RSUs

 

 

Weighted Average Grant Date Fair Value per Share

 

Outstanding as of December 31, 2023

 

 

 

 

1,847,583

 

 

$

10.17

 

RSUs granted

 

 

 

 

1,905,380

 

 

$

13.61

 

RSUs vested

 

 

 

 

(204,511

)

 

$

12.49

 

RSUs forfeited

 

 

 

 

(784,990

)

 

$

13.48

 

Outstanding as of March 31, 2024

 

 

 

 

2,763,462

 

 

$

11.43

 

For RSUs with service-based vesting conditions, the fair value is calculated based upon the Company’s closing stock price on the date of grant, and the stock-based compensation expense is recognized over the applicable grant vesting term, generally four years.

As of March 31, 2024, there was
$31,078 of total unrecognized compensation expense related to options and RSUs expected to be recognized over a weighted average-period of 1.95 years.

The following table summarizes the components of total stock-based compensation expense based on roles and responsibilities of the employees within the condensed consolidated statements of operations:

 

 

 

Three Months Ended March 31,

 

 

 

2024

 

 

2023

 

Cost of revenue

 

$

61

 

 

$

77

 

Research and development

 

 

1,018

 

 

 

651

 

Sales and marketing

 

 

675

 

 

 

437

 

General and administrative

 

 

1,874

 

 

 

1,481

 

 

$

3,628

 

 

$

2,646